Attyloid at AAIC 2026 in London: Enhancing CNS biomarker strategies
How can biomarkers provide a more complete picture of neurodegenerative disease?
We are excited to announce that attyloid will be heading to London for the Alzheimer’s Association International Conference (AAIC) 2026 to help answer this question. Bringing together more than 8,500 researchers, clinicians, and industry innovators from around the glove, this event provides an unparalleled platform for sharing latest breakthroughs in dementia science and CNS drug development.
At the conference, attyloid will highlight how combining complementary biomarker technologies can provide a more comprehensive view of neurodegenerative disease biology and pathology from minimal sample volumes:
- sFIDA®: Highly sensitive quantification and sizing of pathological protein oligomers.
- NULISA™: Ultra-sensitive profiling of hundreds of CNS-relevant protein biomarkers, powered by our partner, Alamar Biosciences, Inc.
Integrating these platforms allows researchers to optimize CNS drug development by gaining complementary insights into disease biology and pathology, understanding treatment responses, assessing target engagement with greater confidence, and making more informed development decisions to save time and resources.
We invite you to visit us at Booth #1303 to discuss how combining sFIDA® and NULISA™ can strengthen your CNS biomarker strategy.
July 12 – 15, 2026 in London, UK